Search

Your search keyword '"Genshen Zhong"' showing total 2 results
Start Over Author "Genshen Zhong" Journal cancer letters
2 results on '"Genshen Zhong"'

1. Novel half-sandwich iridium OˆC (carbene)-Complexes: In vitro and in vivo tumor growth suppression and pro-apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes

Author

Genshen Zhong, Yujiao Zhang, Yuliang Yang, Xianglei Jia, Zhishan Xu, Shumiao Zhang, Qing Du, Zhe Liu, and JuanJuan Li

Subjects
0301 basic medicine, Cancer Research, Antineoplastic Agents, Apoptosis, Mitochondrion, Iridium, Ligands, 03 medical and health sciences, Mice, 0302 clinical medicine, In vivo, Coordination Complexes, Cell Line, Tumor, medicine, Animals, Humans, Cell Proliferation, A549 cell, Mice, Inbred BALB C, Chemistry, Hep G2 Cells, HCT116 Cells, In vitro, Cell biology, Mitochondria, 030104 developmental biology, Oncology, Mechanism of action, Cell culture, A549 Cells, 030220 oncology & carcinogenesis, Cancer cell, Female, medicine.symptom, Lysosomes, Reactive Oxygen Species, HT29 Cells, Methane, HeLa Cells
Abstract

Herein we present half-sandwich IrIII complexes [(η5-Cpxbiph)Ir(OˆC)Cl] containing OˆC(NHC)-chelating ligand as anticancer and antimetastasis agents. All the complexes displayed high potency in vitro against a wide range of cancer cells. In addition, Ir2 significantly curb tumor growth in a colon cancer mouse xenograft model in vivo. Further mechanism of action studies indicate that Ir2-initiated apoptosis occurs through ROS-mediated cross-talk between mitochondria and lysosomes.

Published
2018

2. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice

Author

Yi Li, Rui-Juan Gao, Xiujun Liu, Shenghua Zhang, Genshen Zhong, Qingfang Miao, and Yong-Su Zhen

Subjects
Cancer Research, Gelatinases, Pathology, medicine.medical_specialty, Lung Neoplasms, Proliferation index, Recombinant Fusion Proteins, Mice, Nude, Angiogenesis Inhibitors, Antineoplastic Agents, Mice, Carcinoma, medicine, Enediyne, Animals, Humans, Cell Proliferation, biology, Cancer, medicine.disease, Fusion protein, Xenograft Model Antitumor Assays, Aminoglycosides, Oncology, Tumor progression, Microvessels, biology.protein, Cancer research, Antibody, Enediynes, Apoproteins, Single-Chain Antibodies
Abstract

Gelatinases play important roles in tumor progression and are abundantly expressed in a variety of malignant tumors. Antibody targeting gelatinases is a possible avenue to fight against cancer. However, antibody alone can not achieve curative efficacy. Herein, we demonstrated the intensified targeting therapy of a tandem scFv-based fusion protein and its enediyne-energized analogue against gelatinases-overexpressed tumor. A fusion protein dFv-LDP, comprising a tandem scFv of anti-gelatinases linked to the apoprotein (LDP) of lidamycin, was generated and showed strong tumor targeting capability in three different tumor xenografts. In PG-BE1 lung carcinoma xenograft, the tumor inhibition rate was 77.5% by dFv-LDP versus 94.2% by dFv-LDP-AE, the product of dFv-LDP assembled with the active enediyne chromophore (AE) of lidamycin. Moreover, the combination of dFv-LDP with dFv-LDP-AE further augmented the therapeutic efficacy, producing initial tumor shrinkage in five of six mice. The microvessel density (P

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results